Nivolumab Monotherapy May Yield 8% Complete Response Rate in Urothelial Carcinoma

Share this content:
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation.
The following article features coverage from the 2018 Genitourinary Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

Complete responses may be observed in about 8% of patients with metastatic urothelial carcinoma receiving nivolumab monotherapy regardless of PD-L1 status, according to research being presented at the 2018 Genitourinary Cancers Symposium in San Francisco, California.1

Previous data suggested that nivolumab monotherapy may improve outcomes after progression on at least 1 prior platinum therapy. Here researchers present updated results from the phase 1/2 CheckMate 032 study (ClinicalTrials.gov Identifier: NCT01928394).

Seventy-eight patients with metastatic urothelial carcinoma received intravenous nivolumab until disease progression or discontinuation for other reasons; the median age was 65.5 years and two-thirds of patients had received at least 2 prior therapies.

The minimum follow-up was 24 months. Two-thirds of patients discontinued treatment because of disease progression; 14.1% of patients were still receiving treatment when data were locked. The overall response, progression-free survival (PFS), and overall survival (OS) rates were not affected by PD-L1 status.

The objective response rate was 25.6%, the median PFS was 2.8 months, and the median OS was 10 months; the median response duration was not reached. The complete response rate was 8%.

More than one-fourth (28.2%) of patients had a grade 3 to 4 adverse event; one case of grade 5 pneumonitis was noted.

The authors concluded that nivolumab “showed clinically meaningful, durable efficacy with promising long-term survival regardless of PD-L1 expression, and no new toxicity signals with longer-term follow-up.”

Read more of Cancer Therapy Advisor's coverage of the 2018 Genitourinary Cancers Symposium by visiting the conference page.

Reference

  1. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in metastatic urothelial carcinoma: longer-term efficacy and safety results from the CheckMate 032 study. Oral presentation at: 2018 Genitourinary Cancers Symposium; February 8-10, 2018; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs